Inflammasome‐related gene signatures as prognostic biomarkers in osteosarcoma
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Nan Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, China Coast Guard Hospital of the People's Armed Police Force, Zhejiang, China. Hauptthemen laut MEDLINE: Osteosarcoma, Inflammasomes, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiaxing People's Livelihood Science and Technology Innovation Research Project Fund, Science and Technology Bureau of Jiaxing City.
Abstract (Originalsprache)
Osteosarcoma, the primary bone cancer in adolescents and young adults, is notorious for its aggressive growth and metastatic potential. Our study delved into the prognostic impact of inflammasome‐related gene signatures in osteosarcoma patients, employing comprehensive genetic profiling to uncover signatures linked with patient outcomes. We identified three patient subgroups through consensus clustering, with one showing worse survival rates correlated with high FGFR3 and RARB expressions. Immune profiling revealed significant immune cell infiltration differences among these subgroups, affecting survival. Utilising advanced machine learning, including StepCox and gradient boosting machine algorithms, we developed a prognostic model with a notable c‐index of 0.706, highlighting CD36 and MYD88 as key genes. Higher inflammasome risk scores from our model were associated with poorer survival, corroborated across datasets. In vitro experiments validated CD36 and MYD88's roles in promoting osteosarcoma cell proliferation, invasion and migration, emphasising their therapeutic potential. This research offers new insights into inflammasomes' role in osteosarcoma, introducing novel biomarkers for risk assessment and potential therapeutic targets. Our findings suggest a pathway towards personalised treatment strategies, potentially improving patient outcomes in osteosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, China Coast Guard Hospital of the People's Armed Police Force, Zhejiang, China.
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang, China.
- Key Laboratory of Musculoskeletal System Degeneration and Regeneration Translational Research of Zhejiang Province, Zhejiang, China.
- Department of Orthopaedic Surgery, China Coast Guard Hospital of the People's Armed Police, Zhejiang, China.
ORCID-Profile: Qingxin Wang
Förderung
- Jiaxing People's Livelihood Science and Technology Innovation Research Project Fund
- Science and Technology Bureau of Jiaxing City
Zitieren
APA
Zhang, N., Han, Y., Cao, H., & Wang, Q. (2024). Inflammasome‐related gene signatures as prognostic biomarkers in osteosarcoma. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18286
Vancouver
Zhang N, Han Y, Cao H, Wang Q. Inflammasome‐related gene signatures as prognostic biomarkers in osteosarcoma. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18286
BibTeX
@article{Zhang2024,
author = {Zhang, Nan and Han, Ying and Cao, Hangkai and Wang, Qingxin},
title = {Inflammasome‐related gene signatures as prognostic biomarkers in osteosarcoma},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18286}
}
EUVIMED